Article info

Download PDFPDF

Original article
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice

Authors

  • Niels W Boone Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre Sittard-Geleen, Sittard-Geleen, Limburg, The Netherlands PubMed articlesGoogle scholar articles
  • Alexandre Sepriano Department of Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, The NetherlandsNOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal PubMed articlesGoogle scholar articles
  • Paul-Hugo van der Kuy Department of Clinical Pharmacy, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands PubMed articlesGoogle scholar articles
  • Rob Janknegt Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre Sittard-Geleen, Sittard-Geleen, Limburg, The Netherlands PubMed articlesGoogle scholar articles
  • Ralph Peeters Department of Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Limburg, The Netherlands PubMed articlesGoogle scholar articles
  • Robert B M Landewé Department of Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Limburg, The NetherlandsDepartment of Rheumatology, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands PubMed articlesGoogle scholar articles
  1. Correspondence to Niels W Boone; nwboone{at}gmail.com
View Full Text

Citation

Boone NW, Sepriano A, van der Kuy P, et al
Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice

Publication history

  • Received July 9, 2019
  • Revision received November 7, 2019
  • Accepted November 8, 2019
  • First published November 28, 2019.
Online issue publication 
June 26, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.